Cyclacel Pharmaceuticals Corrects Inadvertent Error in Securities Purchase Agreement

On January 9, 2025, Cyclacel Pharmaceuticals, Inc. made an important announcement regarding an amendment to its Securities Purchase Agreement with David E. Lazar. The Addendum to the Purchase Agreement was established to rectify an inadvertent mistake in the original agreement. The clarification was necessary to accurately reflect the intentions of the involved parties. The Addendum, […]

Leave a Reply

Your email address will not be published.

Previous post Analyzing Revelyst (NYSE:GEAR) and Wrap Technologies (NASDAQ:WRAP)
Next post Canopy Growth (TSE:WEED) Sets New 12-Month Low – Time to Sell?